Scholar Rock Holding (SRRK) Cash from Operations (2017 - 2026)
Scholar Rock Holding's (SRRK) quarterly Cash from Operations came in at 82101000.0 in Q1 2026, down 4.35% year-on-year from 85838963.64 in Q1 2025, and down 8.75% quarter-over-quarter from 75496000.0 in Q4 2025.
Scholar Rock Holding (SRRK) Cash from Operations (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Cash from Operations history runs 10 years deep, the most recent figure standing at 82101000.0 for Q1 2026.
- On a quarterly basis, Cash from Operations fell 4.35% year-over-year to 82101000.0 in Q1 2026; TTM through Mar 2026 was 303461000.0, a 32.03% decrease from a year earlier, with the FY2025 full-year figure at 300035000.0, down 49.31% from the prior year.
- Cash from Operations eased to 82101000.0 in Q1 2026 per SRRK's latest filing, from 75496000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 26483000.0 in Q3 2022 and bottomed at 82101000.0 in Q1 2026.
- The 5-year median for Cash from Operations is 49196000.0 (2024), against an average of 50647352.94.
- Across the five-year window, Cash from Operations gained 26.39% in 2022 and sank 62.54% in 2024, its largest moves.
- Year by year, Cash from Operations stood at 28907000.0 in 2022, then slipped by 29.2% to 37349000.0 in 2023, then plunged by 32.57% to 49513000.0 in 2024, then sank by 52.48% to 75496000.0 in 2025, then declined by 8.75% to 82101000.0 in 2026.
- Per Business Quant, the three latest SRRK Cash from Operations figures stand at 82101000.0 (Q1 2026), 75496000.0 (Q4 2025), and 68923000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Scholar Rock Holding | 6.30 Bn | 6.30 Bn | - | -82.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -82.10 Mn |
| Mar 31, 2026 | -82.10 Mn |
| Dec 31, 2025 | -75.50 Mn |
| Dec 31, 2025 | -75.50 Mn |
| Sep 30, 2025 | -68.92 Mn |
| Sep 30, 2025 | -68.92 Mn |
| Jun 30, 2025 | -76.94 Mn |
| Jun 30, 2025 | -76.94 Mn |
| Mar 31, 2025 | -78.68 Mn |
| Mar 31, 2025 | -78.68 Mn |
| Dec 31, 2024 | -49.51 Mn |
| Dec 31, 2024 | -49.51 Mn |
| Sep 30, 2024 | -52.46 Mn |
| Sep 30, 2024 | -52.46 Mn |
| Jun 30, 2024 | -49.20 Mn |
| Jun 30, 2024 | -49.20 Mn |
| Mar 31, 2024 | -49.79 Mn |
| Mar 31, 2024 | -49.79 Mn |
| Dec 31, 2023 | -37.35 Mn |
| Dec 31, 2023 | -37.35 Mn |